INTRODUCTION: We report successful treatment of mesenteric diffuse large B-cell lymphoma (DLBCL) using localized involved site radiation therapy (ISRT), intensity modulated radiation therapy (IMRT), and daily computed tomography (CT)-image guidance. PATIENTS AND METHODS: Patients with mesenteric DLBCL treated with RT between 2011 and 2017 were reviewed. Clinical and treatment characteristics were analyzed for an association with local control, progression-free survival (PFS), and overall survival. RESULTS: Twenty-three patients were eligible. At diagnosis, the median age was 52 years (range, 38-76 years), and 57% (n = 13) had stage I/II DLBCL. All patients received frontline chemotherapy (ChT) (R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone], n = 19; dose-adjusted R-EPOCH [rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin], n = 4) with median 6 cycles. Prior to RT, salvage ChT for refractory DLBCL was given to 43% (n = 10) and autologous stem cell transplantation was administered in 13% (n = 3). At the time of RT, positron emission tomography-CT revealed 5-point scale of 1 to 3 (48%; n = 11), 4 (9%; n = 2), and 5 (44%; n = 10). All patients received IMRT, daily CT imaging, and ISRT. The median RT dose was 40 Gy (range, 16.2-49.4 Gy). Relapse or progression occurred in 22% (n = 5). At a median follow-up of 37 months, the 3-year local control, PFS, and overall survival rates were 80%, 75%, and 96%, respectively. Among patients treated with RT after complete metabolic response to frontline ChT (n = 8), the 3-year PFS was 100%, compared with 61% for patients with a history of chemorefractory DLBCL (n = 15; P = .055). Four of the 5 relapses occurred in patients with 5-point scale of 5 prior to RT (P = .127). CONCLUSION: Mesenteric involvement of DLBCL can be successfully targeted with localized ISRT fields using IMRT and daily CT-image guidance.
INTRODUCTION: We report successful treatment of mesenteric diffuse large B-cell lymphoma (DLBCL) using localized involved site radiation therapy (ISRT), intensity modulated radiation therapy (IMRT), and daily computed tomography (CT)-image guidance. PATIENTS AND METHODS: Patients with mesenteric DLBCL treated with RT between 2011 and 2017 were reviewed. Clinical and treatment characteristics were analyzed for an association with local control, progression-free survival (PFS), and overall survival. RESULTS: Twenty-three patients were eligible. At diagnosis, the median age was 52 years (range, 38-76 years), and 57% (n = 13) had stage I/II DLBCL. All patients received frontline chemotherapy (ChT) (R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone], n = 19; dose-adjusted R-EPOCH [rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin], n = 4) with median 6 cycles. Prior to RT, salvage ChT for refractory DLBCL was given to 43% (n = 10) and autologous stem cell transplantation was administered in 13% (n = 3). At the time of RT, positron emission tomography-CT revealed 5-point scale of 1 to 3 (48%; n = 11), 4 (9%; n = 2), and 5 (44%; n = 10). All patients received IMRT, daily CT imaging, and ISRT. The median RT dose was 40 Gy (range, 16.2-49.4 Gy). Relapse or progression occurred in 22% (n = 5). At a median follow-up of 37 months, the 3-year local control, PFS, and overall survival rates were 80%, 75%, and 96%, respectively. Among patients treated with RT after complete metabolic response to frontline ChT (n = 8), the 3-year PFS was 100%, compared with 61% for patients with a history of chemorefractory DLBCL (n = 15; P = .055). Four of the 5 relapses occurred in patients with 5-point scale of 5 prior to RT (P = .127). CONCLUSION: Mesenteric involvement of DLBCL can be successfully targeted with localized ISRT fields using IMRT and daily CT-image guidance.
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Mohren; Eva Lengfelder; Marcel Reiser; Christina Nickenig; Michael Clemens; Norma Peter; Carsten Bokemeyer; Hartmut Eimermacher; Anthony Ho; Martin Hoffmann; Roland Mertelsmann; Lorenz Trümper; Leopold Balleisen; Ruediger Liersch; Bernd Metzner; Frank Hartmann; Bertram Glass; Viola Poeschel; Norbert Schmitz; Christian Ruebe; Alfred C Feller; Markus Loeffler Journal: Lancet Oncol Date: 2008-01-15 Impact factor: 41.316
Authors: Sughosh Dhakal; James E Bates; Carla Casulo; Jonathan W Friedberg; Michael W Becker; Jane L Liesveld; Louis S Constine Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-27 Impact factor: 7.038
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Bouthaina Dabaja; Kelly J Perrin; Jorge E Romaguera; Patricia Horace; Christine F Wogan; Ferial Shihadeh; Mohammad R Salehpour Journal: J Med Case Rep Date: 2010-10-19
Authors: Paolo Strati; Sairah Ahmed; Partow Kebriaei; Loretta J Nastoupil; Catherine M Claussen; Grace Watson; Sandra B Horowitz; Anne Rain T Brown; Bryan Do; Maria A Rodriguez; Ranjit Nair; Elizabeth J Shpall; Michael R Green; Sattva S Neelapu; Jason R Westin Journal: Blood Adv Date: 2020-07-14
Authors: Alison K Yoder; Jillian R Gunther; Sarah A Milgrom; Mary Pham; Donald Hancock; Kelli McSpadden; John Garcia; Dragan Mirkovic; Bouthaina S Dabaja; Chelsea C Pinnix Journal: Pract Radiat Oncol Date: 2019-01-29